Search
Sunvozertinib
go.drugbank.com/drugs/DB18925Investigational[L53488] EGFR is a transmembrane protein with cytoplasmic kinase activity commonly expressed by non-small cell lung carcinomas (NSCLCs). … [A274143] Sunvozertinib was granted accelerated approval in the US on July 2, 2025 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor
Amikacin
go.drugbank.com/drugs/DB00479ApprovedInvestigationalVet approvedSymptoms of this disease include a persistent cough, fatigue, weight loss, night sweats, and shortness of breath and the coughing up of blood. … [F1949] In September 2018, a liposomal inhalation suspension of this drug was approved by the FDA for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a small population
Products: AMIKACINA MK 250 MG/MLAbiraterone
go.drugbank.com/drugs/DB05812ApprovedInvestigational[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April,[A260880] July,[L47745] and September 2011,[A260880] respectively. … [L54773,L54768] As abiraterone has poor oral bioavailability and is susceptible to hydrolysis by esterases, abiraterone acetate was developed as an orally bioavailable prodrug with enhanced stability
Edoxaban
go.drugbank.com/drugs/DB09075ApprovedInvestigationalBy inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. … Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for
Milrinone
go.drugbank.com/drugs/DB00235ApprovedInvestigational[A228333] It was approved by the FDA on December 31, 1987, and was marketed under the trademark PRIMACOR® by Sanofi-Aventis US before being discontinued.[L31483] … Heart failure is underpinned by numerous physiological changes, including alteration in β-adrenergic signalling and cyclic adenosine monophosphate (cAMP) production, which affects the heart's contractile
Sarilumab
go.drugbank.com/drugs/DB11767ApprovedInvestigational[A27262] Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approved in May 2017 and followed by EU approval in June 2017 for the treatment of moderate to severe rheumatoid … [A27265] RA is a chronic inflammatory disease characterized by polyarthritis, and its treatment has been challenged by the different responses in every patient.
Glycogen Storage Disease Type Ia
go.drugbank.com/conditions/DBCOND0063604Drugs: Pariglasgene brecaparvovecSynonyms: Hepatorenal form of glycogen storage diseasePlazomicin
go.drugbank.com/drugs/DB12615ApprovedDeveloped by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from [DB12604]. … It mediates the antibacterial activity by binding to bacterial 30S ribosomal subunit and inhibiting protein synthesis [FDA Label].
Trastuzumab
go.drugbank.com/drugs/DB00072ApprovedInvestigationalIn November 2023, trastuzumab was also approved by the EMA under the brand name Herwenda.[L49339] … Kanjinti (trastuzumab-anns)[L14135] and Hercessi[L52840] are other biosimilars approved by the FDA. In Canada, biosimilars ONTRUZANT[[L40303, L40308] and Adheroza[L52835] are approved.
Finafloxacin
go.drugbank.com/drugs/DB09047ApprovedWithdrawnFinafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014. … Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.